Latest Breaking News On - Therapeutic programs - Page 3 : comparemela.com

Senda Biosciences, a company that is systematically harnessing the powerful molecular interactions that have evolved over millennia between humans, plants, and bacteria to develop new types of medicines, announced today the completion of a $55 million Series B extension financing, bringing its total Series B funding to $98 million and total funding raised to date to $143 million. Proceeds from the financing will be used to advance the development of Senda's platform and its therapeutic programs

Flagship pioneeringMolecular interactionsTherapeutic programsSenda biosciencesHuman healthSeriesb fundingNterspecies interactions